Min Ding
40Patents
8h-index
71Co-inventors
78Inventor score
Filing activity: Jan 15, 1999 → Feb 1, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7153848B2 | Inhibitors of HCV replication | Chemistry; Metallurgy | 62 | Expired |
| US7348425B2 | Inhibitors of HCV replication | Chemistry; Metallurgy | 41 | Active |
| US7399758B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | Human Necessities | 13 | Active |
| US9850225B2 | Compounds useful as immunomodulators | Emerging Cross-Sectional Technologies | 11 | Active |
| US7452876B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | Human Necessities | 11 | Active |
| US7456166B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | Human Necessities | 11 | Active |
| US7521442B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | Human Necessities | 9 | Active |
| US7521441B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | Human Necessities | 9 | Active |
| US7538102B2 | Compounds for the treatment of Hepatitis C | Chemistry; Metallurgy | 8 | Active |
| US7485633B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | Human Necessities | 8 | Active |
| US6034113A | Derivatives of 1,3,4-oxadiazolone | Human Necessities | 7 | Expired |
| US7521443B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | Chemistry; Metallurgy | 6 | Active |
| US7541353B2 | Compounds for the treatment of hepatitis C | Human Necessities | 5 | Active |
| US7541351B2 | Compounds for the treatment of hepatitis C | Human Necessities | 5 | Active |
| US7547690B2 | Compounds for the treatment of Hepatitis C | Chemistry; Metallurgy | 4 | Active |
| US9295687B1 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | Performing Operations; Transporting | 3 | Active |
| US8383094B2 | Hepatitis C virus inhibitors | Chemistry; Metallurgy | 3 | Active |
| US8133884B2 | Compounds for the treatment of hepatitis C | Chemistry; Metallurgy | 2 | Active |
| US9439921B2 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | Performing Operations; Transporting | 2 | Active |
| US5948802A | Benzoate derivatives of diaryl 1,3,4-oxadiazolone | Human Necessities | 2 | Expired |
| US10669272B2 | Substituted naphthyridinone compounds useful as T cell activators | Human Necessities | 2 | Active |
| US10039780B2 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | Performing Operations; Transporting | 1 | Active |
| US9738642B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | Chemistry; Metallurgy | 1 | Active |
| US9700575B2 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | Performing Operations; Transporting | 1 | Active |
| US11058672B2 | Pharmaceutical compositions and methods for producing low impurity concentrations of the same | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.